CG Oncology, Inc. SEC filings CGON
CG Oncology, Inc. has 243 filings in SEC EDGAR's recent list, going back to Oct 27, 2023. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 6, 2026 (results of operations, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 12, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2024 | — |
| DRS | Filing | Nov 14, 2024 | — |
| SEC STAFF LETTER | Filing | Jan 26, 2024 | — |
| EFFECT | Filing | Jan 24, 2024 | — |
| CERT | Filing | Jan 24, 2024 | — |
| CORRESP | Letter to the SEC | Jan 22, 2024 | — |
| CORRESP | Letter to the SEC | Jan 22, 2024 | — |
| 8-A12B | Filing | Jan 22, 2024 | — |
| CORRESP | Letter to the SEC | Jan 5, 2024 | — |
| CORRESP | Letter to the SEC | Jan 2, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2023 | — |
| DRSLTR | Filing | Dec 4, 2023 | — |
| DRS/A | Filing | Dec 4, 2023 | — |
| SEC STAFF LETTER | Filing | Nov 27, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 27, 2023 | — |
| DRS | Filing | Oct 27, 2023 | — |
Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CGON (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Dallas, TX
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1991792
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.